Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN)

NCT02176486 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
12
Enrollment
INDUSTRY
Sponsor class

Stopped Insufficient enrollment, no safety or efficacy concerns

Conditions

Interventions

Sponsor

Takeda